These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34110646)

  • 21. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
    Gardaneh M; Shojaei S; Kaviani A; Behnam B
    Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
    PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cooperation of neurotrophin receptor TrkB and Her2 in breast cancer cells facilitates brain metastases.
    Choy C; Ansari KI; Neman J; Hsu S; Duenas MJ; Li H; Vaidehi N; Jandial R
    Breast Cancer Res; 2017 Apr; 19(1):51. PubMed ID: 28446206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer.
    Kanematsu M; Futamura M; Takata M; Gaowa S; Yamada A; Morimitsu K; Morikawa A; Mori R; Hara H; Yoshida K
    Cancer Med; 2015 Sep; 4(9):1344-55. PubMed ID: 26077887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
    Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
    Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synaptamide activates the adhesion GPCR GPR110 (ADGRF1) through GAIN domain binding.
    Huang BX; Hu X; Kwon HS; Fu C; Lee JW; Southall N; Marugan J; Kim HY
    Commun Biol; 2020 Mar; 3(1):109. PubMed ID: 32144388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.
    Yeh ES; Abt MA; Hill EG
    Breast Cancer Res Treat; 2015 Jan; 149(1):91-8. PubMed ID: 25515931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
    Hosonaga M; Arima Y; Sugihara E; Kohno N; Saya H
    Cancer Sci; 2014 Jul; 105(7):779-87. PubMed ID: 24754246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
    Singh JK; Farnie G; Bundred NJ; Simões BM; Shergill A; Landberg G; Howell SJ; Clarke RB
    Clin Cancer Res; 2013 Feb; 19(3):643-56. PubMed ID: 23149820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
    Baldassarre T; Truesdell P; Craig AW
    Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.
    Garcia-Recio S; Fuster G; Fernandez-Nogueira P; Pastor-Arroyo EM; Park SY; Mayordomo C; Ametller E; Mancino M; Gonzalez-Farre X; Russnes HG; Engel P; Costamagna D; Fernandez PL; Gascón P; Almendro V
    Cancer Res; 2013 Nov; 73(21):6424-34. PubMed ID: 24030979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
    Liu D
    Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets in Uterine Corpus Endometrial cancer.
    Lei P; Wang H; Yu L; Xu C; Sun H; Lyu Y; Li L; Zhang DL
    Int Immunopharmacol; 2022 Jul; 108():108743. PubMed ID: 35413679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Significance of G Protein-Coupled Receptor 110 (GPR110) as a Novel Prognostic Biomarker in Osteosarcoma.
    Liu Z; Zhang G; Zhao C; Li J
    Med Sci Monit; 2018 Jul; 24():5216-5224. PubMed ID: 30052620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
    Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PYK2 promotes HER2-positive breast cancer invasion.
    Al-Juboori SI; Vadakekolathu J; Idri S; Wagner S; Zafeiris D; Pearson JR; Almshayakhchi R; Caraglia M; Desiderio V; Miles AK; Boocock DJ; Ball GR; Regad T
    J Exp Clin Cancer Res; 2019 May; 38(1):210. PubMed ID: 31118051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/β-catenin signaling pathway by regulating WNT2.
    Xiu DH; Liu GF; Yu SN; Li LY; Zhao GQ; Liu L; Li XF
    J Exp Clin Cancer Res; 2019 Feb; 38(1):94. PubMed ID: 30791958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. METTL1-mediated tRNA m
    Du D; Zhou M; Ju C; Yin J; Wang C; Xu X; Yang Y; Li Y; Cui L; Wang Z; Lei Y; Li H; He F; He J
    J Exp Clin Cancer Res; 2024 May; 43(1):154. PubMed ID: 38822363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways.
    Guerram M; Jiang ZZ; Yousef BA; Hamdi AM; Hassan HM; Yuan ZQ; Luo HW; Zhu X; Zhang LY
    Oncotarget; 2015 Sep; 6(26):21865-77. PubMed ID: 26068969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.